Scinai Immunotherapeutics Signs Amendment for PinCell Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy SCNI?
Scinai Immunotherapeutics announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under the European Funds for the Modern Economy SMART Path program. The company's revised application seeks EUR 12M in non-dilutive, non-repayable funding to support a EUR 15M integrated R&D program for PC111 a fully human monoclonal antibody targeting soluble Fas Ligand for the treatment of pemphigus vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis, representing 80% project co-financing. The company expects a funding decision within approximately three to four months following submission. The Second Amendment aligns the option timeline with the grant evaluation process. Under the amended terms, the deadline for fulfillment of the option conditions extends to August 31, and the option exercise period extends to September 30.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCNI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCNI
About SCNI
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scinai Immunotherapeutics Reports 2025 Financial Highlights and Strategic Developments
- Doubling CDMO Revenue: In 2025, Scinai's CDMO revenue doubled year-over-year to $1.3 million, reflecting ongoing commercial traction despite a net loss of $8.3 million, indicating challenges in profitability amidst growth.
- Strategic Acquisition and Collaboration: The company completed the acquisition of Recipharm's manufacturing site in Israel in 2026 and entered into a strategic collaboration, enhancing its manufacturing capabilities and broadening service offerings, marking a significant step in its integrated drug development lifecycle.
- Optimized R&D Spending: R&D expenses decreased to $2.4 million in 2025 from $5.5 million in 2024, primarily due to a reallocation of employee and facility costs, which may impact future innovation capabilities despite improving operational efficiency.
- Non-Dilutive Funding Strategy: The company resubmitted its FENG grant application seeking €12 million to support PC111 and IL-17 programs, demonstrating a strategic shift towards capital-efficient funding mechanisms aimed at advancing key projects without diluting shareholder equity.
See More
Scinai Immunotherapeutics Reports 2025 Financial Highlights
- Revenue Growth: Scinai reported revenues of $1.3 million for 2025, an 85% increase from $0.7 million in 2024, indicating ongoing expansion of its CDMO activities, although the overall financial situation remains challenging.
- R&D Expense Reduction: R&D expenses decreased to $2.4 million in 2025 from $5.5 million in 2024, primarily due to a reallocation of employee and facility costs, which may impact future innovation capabilities.
- Widening Net Loss: The company reported a net loss of $8.3 million in 2025, compared to a net income of $4.8 million in 2024, reflecting the absence of financial gains from loan conversions that occurred in 2024, highlighting pressure on profitability.
- Strategic Acquisition: In February 2026, Scinai completed the acquisition of Recipharm's manufacturing site in Israel, expanding its capabilities into small-molecule development and manufacturing, thereby strengthening its position as an integrated CDMO platform, which is expected to enhance customer service capabilities and broaden market reach.
See More
Scinai Immunotherapeutics to Participate in BIO-Europe Spring 2026
- International Conference Participation: Scinai Immunotherapeutics will showcase at BIO-Europe Spring 2026 from March 23-25 in Lisbon, marking its first major international conference following the acquisition of Recipharm Israel, which significantly expands its development and manufacturing capabilities.
- CDMO Platform Advantage: Through its subsidiary Scinai Biopharma Services Ltd., the company offers an integrated CDMO platform from early development to commercialization, leveraging cGMP biologics and small-molecule API development sites in Jerusalem and Yavne, enhancing collaboration potential with biotech and pharmaceutical firms.
- Advancing Antibody Therapy Pipeline: Scinai will present its innovative antibody-based therapeutics pipeline targeting autoimmune and inflammatory diseases, primarily focusing on dermatology, while actively seeking strategic partnerships, co-development, and licensing opportunities with pharmaceutical and biotech companies to advance its pipeline.
- Market Positioning and Strategic Collaboration: CEO Amir Reichman stated that Scinai aims to partner with biotech and pharma companies across all product lifecycle stages, focusing on innovation and execution to meet market demands and further enhance the company's competitive edge.
See More
Scinai Immunotherapeutics Receives Nasdaq Compliance Notice
- Compliance Notice: Scinai Immunotherapeutics received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its American Depositary Shares closed below $1.00 for 30 consecutive business days.
- Compliance Period: The company has been granted 180 calendar days until September 8, 2026, to regain compliance, and if its ADS closing price reaches at least $1.00 for a minimum of 10 consecutive business days during this period, Nasdaq will confirm compliance.
- Stock Price Movement: Following the notification, Scinai's ADS closed down 1.46% at $0.7, reflecting market sensitivity to compliance issues, which may impact investor confidence.
- Trading Impact: The notification does not have an immediate effect on the listing or trading of the company's shares, indicating that the company still has time to take measures to restore compliance.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected within three to four months, thereby providing crucial financial backing for treating severe autoimmune blistering diseases.
- Timeline Adjustments: The Second Amendment to the agreement extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing the project's feasibility.
- Clinical Development Advancement: If awarded, the grant would enable Scinai to advance PC111 through early clinical development and human proof of concept while preserving balance sheet flexibility and minimizing shareholder dilution, strategically laying the groundwork for future R&D initiatives.
- Strengthened Innovation Framework: The revised application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework, ensuring competitiveness in regulatory pathways given the high unmet medical need.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected in approximately three to four months, thereby accelerating treatment development for severe autoimmune diseases.
- Timeline Adjustments: The Second Amendment extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing project feasibility.
- Enhanced Competitiveness: The revised SMART Path program application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework that culminates in integrated non-clinical and First-in-Human datasets to support data-driven progression decisions.
- Strategic Flexibility: If awarded, the grant would enable Scinai to advance PC111 through early clinical development while preserving balance sheet flexibility and minimizing shareholder dilution, ensuring a leading position in a market with high unmet medical needs.
See More
Scinai Immunotherapeutics Reports 2025 Financial Highlights and Strategic Developments
- Doubling CDMO Revenue: In 2025, Scinai's CDMO revenue doubled year-over-year to $1.3 million, reflecting ongoing commercial traction despite a net loss of $8.3 million, indicating challenges in profitability amidst growth.
- Strategic Acquisition and Collaboration: The company completed the acquisition of Recipharm's manufacturing site in Israel in 2026 and entered into a strategic collaboration, enhancing its manufacturing capabilities and broadening service offerings, marking a significant step in its integrated drug development lifecycle.
- Optimized R&D Spending: R&D expenses decreased to $2.4 million in 2025 from $5.5 million in 2024, primarily due to a reallocation of employee and facility costs, which may impact future innovation capabilities despite improving operational efficiency.
- Non-Dilutive Funding Strategy: The company resubmitted its FENG grant application seeking €12 million to support PC111 and IL-17 programs, demonstrating a strategic shift towards capital-efficient funding mechanisms aimed at advancing key projects without diluting shareholder equity.
See More
Scinai Immunotherapeutics Reports 2025 Financial Highlights
- Revenue Growth: Scinai reported revenues of $1.3 million for 2025, an 85% increase from $0.7 million in 2024, indicating ongoing expansion of its CDMO activities, although the overall financial situation remains challenging.
- R&D Expense Reduction: R&D expenses decreased to $2.4 million in 2025 from $5.5 million in 2024, primarily due to a reallocation of employee and facility costs, which may impact future innovation capabilities.
- Widening Net Loss: The company reported a net loss of $8.3 million in 2025, compared to a net income of $4.8 million in 2024, reflecting the absence of financial gains from loan conversions that occurred in 2024, highlighting pressure on profitability.
- Strategic Acquisition: In February 2026, Scinai completed the acquisition of Recipharm's manufacturing site in Israel, expanding its capabilities into small-molecule development and manufacturing, thereby strengthening its position as an integrated CDMO platform, which is expected to enhance customer service capabilities and broaden market reach.
See More
Scinai Immunotherapeutics to Participate in BIO-Europe Spring 2026
- International Conference Participation: Scinai Immunotherapeutics will showcase at BIO-Europe Spring 2026 from March 23-25 in Lisbon, marking its first major international conference following the acquisition of Recipharm Israel, which significantly expands its development and manufacturing capabilities.
- CDMO Platform Advantage: Through its subsidiary Scinai Biopharma Services Ltd., the company offers an integrated CDMO platform from early development to commercialization, leveraging cGMP biologics and small-molecule API development sites in Jerusalem and Yavne, enhancing collaboration potential with biotech and pharmaceutical firms.
- Advancing Antibody Therapy Pipeline: Scinai will present its innovative antibody-based therapeutics pipeline targeting autoimmune and inflammatory diseases, primarily focusing on dermatology, while actively seeking strategic partnerships, co-development, and licensing opportunities with pharmaceutical and biotech companies to advance its pipeline.
- Market Positioning and Strategic Collaboration: CEO Amir Reichman stated that Scinai aims to partner with biotech and pharma companies across all product lifecycle stages, focusing on innovation and execution to meet market demands and further enhance the company's competitive edge.
See More
Scinai Immunotherapeutics Receives Nasdaq Compliance Notice
- Compliance Notice: Scinai Immunotherapeutics received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its American Depositary Shares closed below $1.00 for 30 consecutive business days.
- Compliance Period: The company has been granted 180 calendar days until September 8, 2026, to regain compliance, and if its ADS closing price reaches at least $1.00 for a minimum of 10 consecutive business days during this period, Nasdaq will confirm compliance.
- Stock Price Movement: Following the notification, Scinai's ADS closed down 1.46% at $0.7, reflecting market sensitivity to compliance issues, which may impact investor confidence.
- Trading Impact: The notification does not have an immediate effect on the listing or trading of the company's shares, indicating that the company still has time to take measures to restore compliance.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected within three to four months, thereby providing crucial financial backing for treating severe autoimmune blistering diseases.
- Timeline Adjustments: The Second Amendment to the agreement extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing the project's feasibility.
- Clinical Development Advancement: If awarded, the grant would enable Scinai to advance PC111 through early clinical development and human proof of concept while preserving balance sheet flexibility and minimizing shareholder dilution, strategically laying the groundwork for future R&D initiatives.
- Strengthened Innovation Framework: The revised application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework, ensuring competitiveness in regulatory pathways given the high unmet medical need.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected in approximately three to four months, thereby accelerating treatment development for severe autoimmune diseases.
- Timeline Adjustments: The Second Amendment extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing project feasibility.
- Enhanced Competitiveness: The revised SMART Path program application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework that culminates in integrated non-clinical and First-in-Human datasets to support data-driven progression decisions.
- Strategic Flexibility: If awarded, the grant would enable Scinai to advance PC111 through early clinical development while preserving balance sheet flexibility and minimizing shareholder dilution, ensuring a leading position in a market with high unmet medical needs.
See More
